Product Name: Peceleganan
Form: Acetate salt
CAS No: 850761-47-6
Molar Mass: 2933.5
Chemical Formula: C138H226N36O34
Synonyms: PL-5
Storage: Store at -20℃
Sequence: KWKSFLKTFKSAAKTVLHTALKAISS
Target: antibacterial
Application:
Peceleganan (CAS: 850761-47-6) is a novel synthetic peptide with potential therapeutic applications in various medical fields, particularly in the treatment of infectious diseases. While specific information about peceleganan is limited, it is likely designed to exhibit antimicrobial properties similar to other synthetic peptides by disrupting microbial cell membranes, leading to bacterial or fungal cell death. Peceleganan may offer advantages such as broad-spectrum activity against a range of pathogens, including antibiotic-resistant strains, and a low propensity for inducing resistance. It may be formulated for topical, oral, or systemic administration, depending on the intended use and target infection. Clinical trials and further research are necessary to evaluate the safety, efficacy, and optimal dosing regimens of peceleganan in different patient populations and disease settings.
Current Research:
Peceleganan (also known as PE-01) is a synthetic antimicrobial peptide designed to treat bacterial skin infections. It belongs to the class of cationic peptides, which have garnered attention for their ability to combat a wide range of pathogenic bacteria through mechanisms distinct from traditional antibiotics. Like many antimicrobial peptides (AMPs), peceleganan works by disrupting bacterial cell membranes, which makes it a potential alternative to conventional treatments, particularly in the face of rising antibiotic resistance.
Mechanism of Action
Peceleganan exerts its antimicrobial effect through a mechanism typical of cationic antimicrobial peptides. The peptide contains positively charged amino acid residues that allow it to interact with the negatively charged bacterial cell membrane, which contains phospholipids or lipopolysaccharides. This interaction leads to the formation of pores in the bacterial membrane, resulting in leakage of essential intracellular components, cell lysis, and ultimately bacterial death.
One of the key advantages of peceleganan, as with other AMPs, is that it does not rely on traditional enzymatic pathways or specific bacterial proteins. Instead, it acts through the physical disruption of bacterial membranes, which means that bacteria are less likely to develop resistance to it over time. This is particularly significant as multidrug-resistant (MDR) pathogens continue to pose a major challenge in infection control.
Clinical Applications
Peceleganan has primarily been investigated for the treatment of skin infections, particularly those caused by Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Escherichia coli. These bacteria are common culprits in both acute and chronic skin infections, which can range from superficial infections to deep wounds and burns.
While the peptide is still in the early stages of clinical development, preclinical studies and early-stage clinical trials have suggested that peceleganan may be effective in treating diabetic foot infections (DFI), chronic wounds, and other superficial bacterial skin infections. These infections often involve biofilm formation, which provides bacteria with protection against conventional antibiotics. Peceleganan's ability to disrupt bacterial membranes and penetrate biofilms is one of its most promising features.
Advantages Over Traditional Antibiotics
Broad-Spectrum Activity: Peceleganan is effective against a wide array of Gram-positive and Gram-negative bacteria. This broad-spectrum action makes it suitable for treating mixed infections, which are common in skin conditions like diabetic foot ulcers or surgical wounds.
Low Likelihood of Resistance: Like many antimicrobial peptides, peceleganan's mechanism of action (membrane disruption) makes it less prone to resistance compared to traditional antibiotics, which are often targeted at specific bacterial enzymes or proteins. As antibiotic resistance becomes a growing problem, AMPs like peceleganan could play a key role in combating infections caused by resistant strains.
Topical Administration: As a topical agent, peceleganan can be applied directly to the site of infection. This limits the risk of systemic side effects, such as those associated with oral or intravenous antibiotics. This is particularly advantageous for patients with localized infections, such as those with chronic wounds or burns, who may not require systemic therapy.
Effectiveness Against Biofilm: Peceleganan has been shown to disrupt biofilm formation in bacterial cultures, which is a major concern in chronic infections. Biofilms are protective layers that allow bacteria to survive in hostile environments, making them resistant to conventional antibiotics. Peceleganan’s ability to disrupt these biofilms could help clear persistent infections that are difficult to treat with traditional antibiotics.
Safety and Tolerability: Early clinical trials have suggested that peceleganan has a favorable safety profile when applied topically. Most reported side effects have been mild and localized, such as skin irritation or redness at the site of application. This makes it a potentially safer option for long-term or repeated use in patients with chronic infections, such as those with diabetes or immunocompromised conditions.
Clinical Trials and Efficacy
Peceleganan has been tested in several preclinical studies and early-phase clinical trials for its efficacy in treating diabetic foot infections and other cutaneous bacterial infections. In some Phase 2 trials, peceleganan demonstrated comparable or superior efficacy to oral antibiotics like moxifloxacin in terms of reducing bacterial load and promoting wound healing. Additionally, the topical application of peceleganan reduced the risk of systemic side effects that are commonly associated with oral or intravenous antibiotics.
Though further Phase 3 clinical trials are needed to confirm its efficacy and safety in larger patient populations, initial results have been promising. Peceleganan has shown a rapid onset of action, with noticeable reductions in infection symptoms, such as redness, swelling, and exudate production.
Safety and Tolerability
One of the major advantages of peceleganan is its favorable safety profile. Since it is applied topically, it has a low risk of systemic toxicity. The most common side effects observed in clinical trials have been local skin reactions, such as irritation, itching, and redness at the application site. These reactions are typically mild and transient, resolving once the treatment is discontinued.
Unlike systemic antibiotics, which can cause a range of side effects—such as gastrointestinal distress, nephrotoxicity, or liver toxicity—peceleganan’s localized application minimizes the risk of such issues. This makes it an ideal treatment for patients with chronic skin conditions or those requiring long-term therapy, such as those with diabetic foot ulcers or surgical wounds.
Future Directions
The potential uses for peceleganan extend beyond diabetic foot infections and chronic wounds. Ongoing research is exploring its role in treating burns, surgical site infections, wound infections, and superficial skin infections caused by resistant pathogens like MRSA. Given its broad-spectrum activity and ability to penetrate biofilms, peceleganan may offer a promising solution for treating infections that are difficult to manage with traditional antibiotics.
Future studies will also explore the potential of combining peceleganan with other antimicrobial agents or biofilm-disrupting compounds to enhance its efficacy. Furthermore, the development of novel formulations for enhanced penetration and sustained release could expand its therapeutic potential.
Conclusion
Peceleganan represents a promising addition to the arsenal of treatments for skin infections, particularly in the context of chronic wounds, diabetic foot infections, and burns. Its broad-spectrum activity, low resistance potential, and localized application make it a strong candidate for use in managing infections caused by multidrug-resistant bacteria. As research progresses, peceleganan may become an essential tool in addressing the growing challenge of antibiotic resistance in skin infections and other superficial bacterial infections.
Reference:
Get a Quote
LinkPeptide
